UNSPSC 51313401: Chlorphenamine or chlorpheniramine or dexchlorpheniramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U6IO1965U, chemically known as 3-(p-chlorophenyl)-3-(2-pyridyl)-n,n-dimethylpropylamine but generally known as chlorphenamine, which bears US NIH Compound Identifier 2725. European Medicines Agency schedules Chlorphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06201MIG.

UNSPSC 51313401 Chlorphenamine or chlorpheniramine or dexchlorpheniramine is a Commodity code covering pharmaceutical antihistamines that state and local health agencies procure for emergency response, public health programs, and community health initiatives. Recent state and local solicitations show governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing agreements, and exploring direct-to-manufacturer prescription programs. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement appear as active recent buyers.

Activity under this code concentrates in Florida and Minnesota, with broader multistate reach through cooperative vehicles like MMCAP that serve participating state and local government facilities across multiple states including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with contract effectiveness July 1, 2026.